The apicomplexan parasite Toxoplasma gondii does not possess complex I of the mitochondrial respiratory chain, but has two genes encoding rotenone-insensitive, non-proton pumping type-II NADH dehydrogenases (NDH2s). The absence of such "alternative" NADH dehydrogenases in the human host defines these enzymes as potential drug targets. TgNDH2-I and TgNDH2-II are constitutively expressed in tachyzoites and bradyzoites and are localized to the mitochondrion as shown by epitope tagging. Functional expression of TgNDH2-I in the yeast Yarrowia lipolytica as an internal enzyme, with the active site facing the mitochondrial matrix, permitted growth in the presence of the complex I inhibitor DQA. Bisubstrate kinetics of TgNDH2-I measured within Y. lipolytica mitochondrial membrane preparations were in accordance with a ping-pong mechanism. Using inhibition kinetics we demonstrate here that 1-hydroxy-2-alkyl-4(1)quinolones with long alkyl chains of C 12 (HDQ) and C 14 are high affinity inhibitors for TgNDH2-I, while compounds with shorter side chains (C 5 and C 6 ) displayed significantly higher IC 50 values. The efficiency of the various quinolone derivatives to inhibit TgNDH2-I enzyme activity mirrors their inhibitory potency in vivo, suggesting that a long acyl site chain is critical for the inhibitory potential of these compounds.
Introduction
NADH:ubiquinone oxidoreductases, also known as NADH dehydrogenases constitute one of the electron entry points into the respiratory chain, oxidizing NADH and generating ubiquinol. In eukaryotes, this class of enzymes is divided into two major subfamilies, which can be discriminated on the basis of cofactor content and sensitivity towards rotenone into type-I NADH dehydrogenases (complex I) and type-II NADH dehydrogenases (NDH2s) [1] . Proton-pumping complex I is a nearly ubiquitous enzyme that couples the rotenone-sensitive transfer of electrons from NADH to ubiquinone with the active transport of protons across the inner mitochondrial membrane [2] . Bacterial complex I typically consists of fourteen subunits that are homologous to the seven mitochondrially coded and the seven nuclear coded "central" subunits of the eukaryotic enzyme. Although eukaryotic complex I contains a variable number of so-called accessory subunits, with a total of 45 subunits and a molecular mass of roughly 1 MDa in mammals, the bioenergetic function and the overall structure are conserved [3, 4] .
In contrast to complex I, type-II NADH dehydrogenases are nonproton-pumping, rotenone-insensitive, single polypeptides. Their active site can face either to the cytosol (external enzymes), thereby oxidizing cytosolic NADH, or to the mitochondrial matrix (internal enzymes), thereby oxidizing mitochondrial NADH. Seven NDH2 isoforms are expressed in Arabidopsis, three of them are identified as internal enzymes, whereas the other four are external [5] . In Saccharomyces cerevisiae mitochondria lacking complex I, one internal and two external enzymes have been described [6] .
Type-II NADH dehydrogenases have been described in plants, fungi, protozoa and bacteria [1, 7] , but appear to be absent in mammals, which qualifies them as attractive drug targets. The apicomplexan parasites Plasmodium falciparum and Toxoplasma gondii, which are the causative agents of malaria and toxoplasmosis respectively, both lack complex I. Instead, the genome of P. falciparum is predicted to encode a single NDH2 of unknown orientation, while the T. gondii genome encodes two NDH2 isoforms. Treatment of P. falciparum with micromolar concentrations of diphenylene iodonium chloride, a low affinity inhibitor of NDH2, resulted in an inhibition of PfNDH2 activity, in a collapse of the parasite's mitochondrial membrane potential and finally in parasite death [8] .
The quinolone-like compound 1-hydroxy-2-dodecyl-4(1)quinolone (HDQ) was described as the first high affinity inhibitor of type-II NADH dehydrogenases that inhibits NDH2 activity in mitochondrial membranes of the yeast Yarrowia lipolytica with an IC 50 of 200 nM [9] . We have recently shown that HDQ is highly effective against T. gondii and inhibits parasite replication with an IC 50 in the nanomolar range [10] . Moreover, a combined treatment of HDQ with the complex III inhibitor atovaquone resulted in synergism [10] .
To further elucidate the suitability of type-II NADH dehydrogenases as drug targets it is crucial to obtain functional data from pathogen orthologs and to determine their interaction with putative inhibitors. We here report functional expression of TgNDH2-I in the yeast Y. lipolytica. This allowed us to study the kinetics of this enzyme and to demonstrate that 1-hydroxy-2-alkyl-4(1)quinolones with long alkyl side chains are high affinity inhibitors for TgNDH2-I.
Materials and methods

Genome data mining and sequence analyses
Preliminary genomic and/or cDNA sequence data were accessed via http://ToxoDB.org (version 3.0) [11] and/or http://tigr.org/tdb/t_gondii/. Genomic data were provided by the Institute for Genomic Research (NIH grant #AI05093), and by the Sanger Center (Wellcome Trust). EST sequences were generated by Washington University (NIH grant #1R01AI045806-01A1). Bioinformatics programs including MitoProt II 3.0 (http://ihg.gsf.de/ihg/mitoprot.html) and SignalIP 3.0 (http://ww.cgs. dtu.dk/services/SignalIP/) were used to predict subcellular location of Tgndh-I and Tgndh2-II.
Determination of the ATG initiation codons
An in-frame stop codon is present at 783 and 51 nt upstream of the presumed initiation ATG codons of tgndh2-I and tgndh2-II respectively. The deduced amino acid sequences coded by these regions have no other in-frame methionine residues and no similarity to NDHs nor to other proteins when blasted using NCBI BLAST. For tgndh2-I the next methionine residue is located 177 nt downstream of the first one. However, only the amino acid sequence deduced from the first ATG has characteristics of a mitochondrial targeting sequence. For tgndh2-II, a putative second start ATG is located 6 nt downstream of the first.
RNA extraction, RT-PCR and fusion-PCR
Total RNA was isolated using the GenElute Mammalian Total RNA Kit (Sigma) and treated with DNase I (Sigma). Reverse transcription (RT) was done on 5 μg of total RNA, Oligo(dT) primer (Sigma) and M-MLV reverse transcriptase (RNase H minus, Sigma) according to the manufacturer's instructions. For PCR amplification, the reaction mixture was cycled in a thermal cycler. Fusion-PCR amplification was firstly performed in a volume of 50 μl containing 50 ng of each purified DNA fragment (QIAquick PCR purification kit, Qiagen) with 5 cycles of PCR in the absence of primers. The PCR reaction was continued for another 7 cycles after adding the primer sets (BamHI-NUAM-Fusion+ with NDH2-I-FL− or NDH2-II-FL−).
Real-time PCR
Light cycler PCR (Roche) was performed to amplify cDNA of tgndh2-I, tgndh2-II and β-tubulin with the following primer sets RT-AND1/1+ and 2−, RT-AND2/1+ and 2−, and RT-Tub/3+ and 4−, as listed in Supplementary Table 1. A control sample without reverse transcriptase was incubated in parallel. The threshold crossing-point values of tgndh2-I and tgndh2-II were normalized to that of β-tubulin.
Immunofluorescence microscopy
Samples were fixed with 4% paraformaldehyde/PBS for 10 min and permeabilized with 0.25% Triton X-100/PBS for 15 min. After blocking for 1 h with 1% BSA/PBS, samples were incubated with a 1:250 dilution of anti-myc mAb 9E10 (Sigma) followed by incubation with a 1:500 dilution of Cy3-conjugated anti-mouse IgG (Dianova) in 1% BSA/PBS for 1 h each.
T. gondii strains, cultivation and in vitro stage conversion
Parasites were propagated in human foreskin fibroblasts (HFF) as previously described [12] . A clonal isolate of the RH strain was used for in vitro stage conversion and preparation of cDNA for real time RT-PCR analysis. Transactivator expressing T. gondii of strain RH TATi-1 [13] were kindly provided by Dr. D. Soldati and Dr. M. Meissner and used for transfection experiments. Bradyzoites obtained by in vitro stage conversion were prepared as follows. T. gondii infected HFFs were firstly cultivated in 1% FCS/DMEM for 3 h at 37°C in a 5% CO 2 humidified atmosphere. The medium was subsequently replaced with pH-shift medium (pH 8.3) to induce bradyzoite differentiation [14] and the cultures were incubated at 37°C without CO 2 . The medium was changed daily with fresh pH-shift medium to remove the extracellular parasites and maintain a constant culture pH. After 4-day incubation, cells were detached and harvested for RNA isolation.
Generation of myc-tagged Tgndh2-I and Tgndh2-II for expression in parasites
The complete open reading frames (ORF) of Tgndh2-I and Tgndh2-II were amplified from cDNA of the RH strain using Pfu polymerase (Promega) with the primer sets AND1/ORF1+_AflII and AND1/ORF2−_ AvrII, and AND2/ORF1+_NsiI and AND2/ORF2_AvrII, respectively. The PCR fragments were cloned into pCR4.0-TOPO (Invitrogen) and DNA sequenced. The AflII/AvrII and NsiI/AvrII fragments were finally subcloned into pTetO7Sag4-acyl carrier protein (ACP)-cmyc-DHFR vector (kindly provided by Dr. B. Striepen), thereby replacing the ACP ORF with the Tgndh2-I and Tgndh2-II ORFs. The final constructs pTetSag4-ndh2-I-cmyc-DHFR and pTet7Sag4-ndh2-II-cmyc-DHFR consisted of the anhydrotetracycline (Atc)-regulable TetO7Sag4 promoter element [15] , which controls the expression of the complete Tgndh2-I and Tgndh2-II ORFs with a C-terminal myc-tag, and additionally includes a pyrimethamine resistance cassette for selection [16] . Parasites (2 × 10 7 ) were electroporated with 50 μg of NotIlinearized constructs as previously described [12] . Not I (25 U) was added to the cytomix before electroporation in order to increase the frequency of stable transfectants [17] . Stably transfected parasites were selected with 1 μM pyrimethamine.
Plasmid construction and Y. lipolytica transformation
The NUAM-Tgndh2s fusion constructs were generated as translational fusions comprising the Y. lipolytica mitochondrial targeting sequence of the complex I NUAM subunit [18] and the corresponding Tgndh2-I or Tgndh2-II mature peptides. The NUAM DNA fragments were amplified by PCR from plasmid pUB38 [19] using proof-reading Phusion DNA polymerase (Finnzymes' Phusion high-fidelity DNA polymerase, NEB) with sense primer BamHI-NUAM-Fusion+ and the corresponding antisense primers YL-NDH2-I-24−, YL-NDH2-I-51− and YL-NDH2-II-62− (Supplementary Table S1 ). For obtaining DNA fragments for the mature parts of the Tgndh2-I-(AA24), Tgndh2-I-(AA51) and Tgndh2-II-(AA62) constructs, cDNA isolated from the RH strain was used as a template for PCR amplification with the following primer sets: YL-NDH2-I-24+ and NDH2-I-FL−, YL-NDH2-I-51+ and NDH2-I-FL, and YL-NDH2-II-62+ and NDH2-II-FL−, respectively. The NUAM-Tgndh2 fusions were achieved by fusion-PCR. To create the Tgndh2s full-length constructs, primer sets NDH2-I-FL+ and NDH2-I-FL− for Tgndh2-I, and NDH2-II-FL+ and NDH2-II-FL− for Tgndh2-II were used as shown in Supplementary Table S1. All PCR fragments were cloned into pDrive vector (PCR cloning kit, Qiagen) according to the manufacture's protocol, and then subcloned into the BamHI and EcoRI sites of the Y. lipolytica/E. coli shuttle vector pUB30 [19] , behind the pPOX2 promoter. All clones were sequenced and confirmed with correct orientation. Y. lipolytica haploid NDH2 deletion strain GB5.2 [20] was used for transformation with pUB30 constructs encoding TgNDH2-I and TgNDH2-II full-length, or NUAMTgNDH2-I and NUAM-TgNDH2-II fusion constructs. Transformants were grown in rich glucose medium in the presence of 100 µg/ml Hygromycin B.
Preparation of mitochondrial membranes
Mitochondrial membranes were isolated as previously described [9] . In brief, cells were harvested and resuspended in ice-cold buffer containing 600 mM sucrose, 20 mM Na + /Mops, pH 7.4, 1 mM EDTA, and 2 mM phenyl-methylsulfonyl fluoride, and disrupted by glass beads. Mitochondrial membranes were collected from the supernatant and further homogenized, shock-frozen and stored at −80°C. Samples were aliquoted for kinetic measurements and protein determination.
Kinetic measurements
NADH:DBQ oxidoreductase activity of mitochondrial membranes from Y. lipolytica expressing Tgndh2-I and Tgndh2-II was measured at 30°C in a reaction mixture containing 20 mM Na + /Mops (pH 7.4), 50 mM NaCl, 2 mM KCN, 0.1 μM NADH, 60 μM DBQ, and 100 μg/ml mitochondrial membranes in the presence of 27 μM complex I inhibitor DQA. The reaction was initiated by adding DBQ and monitored using a plate reader spectrophotometer (SPECTRAmax PLUS 384, Molecular Devices). Enzyme activities were recorded in terms of velocity (v, unit:
). The applied DBQ concentrations were in the range from 2.5-100 µM (at 100 µM NADH) and the NADH concentrations were in the range from 10-100 µM (at 60 µM DBQ). Data were analysed according to the equations detailed in [9] . Determination of Michaelis-Menten parameters was by direct fit using the ENZFITTER software package (Biosoft, Cambridge). HDQ and HDQ analogues were kindly provided by Dr. W. Oettmeier and were dissolved in tissue culture grade DMSO (Sigma).
Nucleotide sequence accession numbers of Tgndh2-I and Tgndh2-II genes
Sequence data of Tgndh2-I and Tgndh2-II were submitted to GenBank with accession numbers DQ211932 and DQ228957, respectively.
Results
T. gondii expresses two mitochondrial NDH2 isoforms but no complex I
Based on BLAST homology searches, the genome of T. gondii is predicted to encode conventional respiratory chain components, with the exception of the multi-subunit, proton-translocating NADH Fig. 1 . Mitochondrial localization of myc-tagged TgNDH2-I and TgNDH2-II in parasites. RH strain tachyzoites were transfected with expression plasmids (pTetO7Sag4-NDH2-I/IIcmyc-DHFR), harboring the complete ORFs of TgNDH2-I and TgNDH2-II. The myc-tagged fusion proteins were detected by immunofluorescence staining using anti-myc mAB 9E10. For co-localization experiments, stably transfected parasites expressing the ectopic TgNDH2-I and TgNDH2-II genes were co-transfected with pCAT S9-GFP, which encodes a mitochondrially targeted GFP fusion. dehydrogenase known as complex I. Instead, two contigs (TGG_994254 and TGG_994290) with high similarities to type-II NADH dehydrogenases were identified in the ToxoDB. The complete open reading frames of both genes were amplified, subcloned and sequenced from T. gondii RH strain cDNA. The two genes encoding the type-II NADH dehydrogenases were designated as tgndh2-I (accession#: DQ211932) and tgndh2-II (accession#: DQ228957). They encode precursor polypeptides of 619 and 657 amino acids with predicted masses of 67.1 and 72.1 kDa, respectively. Information on gene structures is given in Supplementary Fig. S1 . The deduced primary structure of both proteins includes N-terminal mitochondrial targeting sequences as predicted by MitoProt II and SignalP 3.0. To verify the mitochondrial localization of TgNDH2-I and TgNDH2-II, we performed epitope tagging experiments. The complete open reading frames (ORF) of both genes were fused to a Cterminally located c-myc epitope and the resulting expression plasmids (pTetO7Sag4-NDH2-I/II-cmyc-DHFR) were introduced into RH strain parasites of the TATi-1 line by electroporation. Immunofluorescence analysis of stably transfected parasite populations revealed that both isoforms were targeted to the single T. gondii mitochondrion as confirmed by co-localization with the mitochondrial marker S9-GFP [21] that had been co-transfected into NDH2-myc expressing parasites (Fig. 1) . We examined tgndh2-I and tgndh2-II transcript levels in the two parasitic stages (tachyzoites and bradyzoites), which are present in the human host by quantitative real time RT-PCR. Both genes displayed comparable mRNA levels in the analyzed stages (Fig. 2) , suggesting that they were constitutively expressed rather than stage specifically regulated.
Functional expression of TgNDH2-I in Y. lipolytica
The yeast Y. lipolytica expresses a single, external, non-essential NDH2 and has been established as a model organism for studying the biochemistry of alternative NADH dehydrogenases [22] and of respiratory chain complex I [23] . We used Y. lipolytica strain GB 5.2, in which the external NDH2 was deleted, for heterologous expression of TgNDH2-I and TgNDH2-II. It is not known whether a mitochondrial import sequence from a T. gondii protein is sufficient for accurate targeting into Y. lipolytica mitochondria. Thus, in addition to fulllength T. gondii constructs, we also employed fusions of the Nterminal part of the Y. lipolytica mitochondrial NUAM protein and mature versions of TgNDH2-I and TgNDH2-II. The predicted start position for mature TgNDH2-I is at amino acid 24 and for mature TgNDH2-II at amino acid 62 (Fig. 3A) . The predicted presequence for TgNDH2-I is relatively short and after a manual sequence alignment with TgNDH2-II, a second, although less likely start position for mature TgNDH2-I was identified at position 51 and used for NUAM fusion. It has been demonstrated previously that the addition of the NUAM mitochondrial import signal to the external Y. lipolytica NDH2 is sufficient to convert this enzyme into an internal, enzymatically active isoform [18] . All constructs were placed under the control of the pPOX2 promotor in the replicative vector pUB30 [19] . Mitochondrial membrane preparations of Y. lipolytica transformants were analyzed for NADH dehydrogenase activity in an enzymatic assay using DBQ as electron acceptor. The NUAM-TgNDH2-I fusions displayed electron transfer activities that were 10-fold (construct A: AA24) and 5-fold (construct B: AA51) higher than controls, demonstrating that this isoform can be expressed as an active enzyme in Y. lipolytica (Fig. 3B) . Both TgNDH2-II constructs displayed electron transfer activities that were less than 2-fold above controls, and the activity of full-length TgNDH2-I was less than 2.5-fold above controls.
Complex I, the proton-translocating multi-subunit NADH dehydrogenase of the mitochondrial respiratory chain, is essential for growth of Y. lipolytica. The ability of the five expression constructs to compensate for the loss of complex I activity was tested in a Y. lipolytica growth assay on YPD agar plates in the presence of the complex I inhibitor DQA. Expression of TgNDH2-I as NUAM fusion proteins conferred DQA resistance (Fig. 3C ), in line with the results obtained from the enzyme activity assay. This demonstrated that both NUAMTgNDH2-I fusions were expressed as functional, internal enzymes with their active site oriented towards the mitochondrial matrix. NUAM-TgNDH2-I expressed from construct A which displayed the highest activity and was used in all kinetic assays and is termed TgNDH2i in the following.
TgNDH2i activity is effectively inhibited by 1-hydroxy-2-alkyl-4(1H) quinolones
The quinolone-like compound HDQ is a potent inhibitor of Y. lipolytica NDH2 [9] and our recent findings have shown that HDQ could effectively inhibit T. gondii replication [10] . We thus investigated the inhibitory effect of HDQ on the NADH dehydrogenase activity of TgNDH2i in unsealed Y. lipolytica mitochondrial membranes. Using DBQ as a substrate, inhibition of NADH:ubiquinone oxidoreductase activity by HDQ was dose dependent with a concentration required for half-maximal inhibition (IC 50 ) of about 300 nM (Fig. 4A) . A 1-hydroxy-2-alkyl-4(1H)quinolone compound with a C 14 alkyl side chain (HTQ, Fig. 4B ) displayed a similar IC 50 as HDQ (C 12 ), while derivates with shorter alkyl side chains (C 5 =HPQ and C 6 = HHQ) were less effective with significantly higher IC 50 values of about 3700 nM and 2300 nM, respectively (Fig. 4C, D) .
TgNDH2i bisubstrate kinetics suggest a ping-pong reaction mechanism
Mitochondrial membrane preparations from Y. lipolytica expressing TgNDH2i were used to determine bisubstrate kinetics for NADH and DBQ. K m values of 76 µM for NADH and 14 µM for DBQ were obtained. In a Hanes plot ([S]/v over [S]) of the kinetic data, the obtained lines crossed close to the y-axis (Fig. 5) , which is in accordance with a ping-pong reaction mechanism for TgNDH2i [9] . A (random or ordered) sequential mechanism could be excluded since in that case the lines would cross in the fourth quadrant. This result suggests that the enzyme forms binary complexes with each of the substrates, but is unable to form a ternary complex with both substrates. Most likely, both substrates interact with a common binding site in a mutually exclusive fashion.
HDQ inhibition follows a non-competitive pattern for both substrates
To determine the mode of inhibition of HDQ on TgNDH2i in mitochondrial membrane preparations from Y. lipolytica, we performed steady-state inhibition kinetics for both NADH and DBQ. Double reciprocal plots of the kinetic data obtained in the presence of 0, 60 and 300 nM HDQ are depicted in Fig. 6 . With increasing HDQ concentrations, the slopes increased, and the lines intersected close to the y-axis. Similar as found with Y. lipolytica NDH2 [9] , these results formally follow the pattern of non-competitive inhibition for both substrates and similar values for the two inhibition constants (see Supplementary Fig. S2 ). Using linear secondary plots of the slopes and y-axis intercepts of the lines in Fig. 6 against the HDQ concentrations used, numeric values for the inhibition constants could be derived from the points of intersection with the x-axis (see Supplementary Fig. S3 ). Secondary plots of the slopes thus gave K i = 283 nM and K ii = 292 nM, and secondary plots of the intercepts gave K i = 234 nM and K ii = 198 nM. Within experimental error, these results are in excellent agreement with the directly determined IC 50 value for HDQ on TgNDH2i and with the assumption that K i equals K ii .
Discussion
In this study we have determined enzymatic parameters from heterologously expressed, functionally active T. gondii NDH2-I and could show that 1-hydroxy-2-alkyl-4(1)quinolones with long alkyl chains are high affinity inhibitors for this enzyme. T. gondii lacks complex I but possesses two mitochondrial type-II NADH dehydrogenases. Both are constitutively expressed, hampering direct determination of individual enzymatic parameters in T. gondii lysates. Thus, for in vitro characterization, we have expressed TgNDH2-I in a strain of the yeast Y. lipolytica that lacks endogenous alternative NADH dehydrogenase activity. Functional expression of TgNDH2-I as an internal NADH dehydrogenase, capable of electron transfer from matrix NADH to membrane bound ubiquinone, was achieved by fusing the TgNDH2-I open reading frame without the endogenous mitochondrial targeting sequence to the N-terminal part of the NUAM subunit of Y. lipolytica mitochondrial complex I. Direct evidence for in vivo function of TgNDH2i was provided by the observation that expression of the transgene allowed cells of Y. lipolytica to survive in the presence of the complex I inhibitor DQA. Thus we were able to achieve heterologous expression of a protozoan type-II NADH dehydrogenase in an active form. Functional expression of protozoan type-II NADH dehydrogenases in Y. lipolytica should facilitate future comparative studies of apicomplexan orthologs. In addition, expression of protozoan type-II enzymes in Y. lipolytica could be used for the development of a screening assay to identify novel, specific inhibitors for this class of enzymes.
The steady-state inhibition kinetics of TgNDH2-I for the quinolone derivative HDQ were found to be very similar to those of Y. lipolytica NDH2 [9] and formally follow the pattern of non-competitive inhibition for both substrates, NADH and DBQ. In the case of a pingpong reaction mechanism, this inhibition pattern is predicted when the inhibitor blocks both the enzyme, here TgNDH2i-FAD and the intermediate form, here TgNDH2i-FADH 2 [24] . As with Y. lipolytica NDH2 [9] , our data thus support a model in which the inhibitor can interact with a complex consisting of the enzyme and one of its substrates, presumably NADH, as depicted in Supplementary Fig. S2 .
Bisubstrate kinetics revealed that the NADH:DBQ oxidoreductase activity of TgNDH2i followed a ping-pong reaction mechanism, a mode of action that was also shown for the Y. lipolytica ortholog [9] and proposed for the S. cerevisiae and T. brucei enzymes [25, 26] . The determined K m (NADH) of 76 µM was significantly higher than the K m of most other eukaryotic enzymes, for example from S. tuberosum, N. crassa and S. cerevisiae, which were in the range of 11-32 µM [7] . Only the T. brucei enzyme with 120 µM displayed a higher K m than the T. gondii ortholog [26] . Also, the K m (DBQ) of 14 µM observed for TgNDH2i was higher than the K m (DBQ) of 7.0 µM for Y. lipolytica NDH2 [9] . However, differences in K m values have to be interpreted with caution, since different electron acceptors were used in these studies and specific reaction conditions as the volume of the lipid phase could influence activities. Since the activity of TgNDH2i was about 4-fold lower than the activity of NDH2, the external alternative NADH dehydrogenase of Y. lipolytica parental strains, we had to double the amount of total mitochondrial protein used in the assays. Lower effective concentrations of DBQ in the lipid phase would explain the elevated K m (DBQ) values observed in the present study. In contrast, the K m (NADH) is not expected to depend on the volume of the lipid phase.
The IC 50 value of about 300 nM obtained for HDQ indicates that this compound is a high affinity inhibitor for TgNDH2-I. The only other NDH2 enzyme for which the IC 50 value for HDQ is known is the Yarrowia orthologue, which with 200 nM is in the same range [9] . In the future, it will be important to determine IC 50 values for further orthologues from pathogenic and non-pathogenic microorganisms, in order to classify HDQ as a broad spectrum NDH2 inhibitor or as an inhibitor with a selected inhibitory potential. An example for a respiratory chain inhibitor with a selected inhibitory potential is the clinically approved antimalaria drug atovaquone. This drug is a complex III inhibitor that interferes with the ubiquinol oxidation site of the cytochrome bc 1 complex by acting as a competitive inhibitor for ubiquinol. Atovaquone possesses antimicrobial activity against certain apicomplexan parasites such as Plasmodium and Toxoplasma and the opportunistic fungal pathogen Pneumocystis carinii, whereas the human and bovine cytochrome bc 1 complexes are insensitive towards atovaquone [27] .
For HDQ, the in vitro IC 50 of~300 nM for inhibition of TgNDH2i activity is significantly higher than the in vivo IC 50 of 2-4 nM for static effects on T. gondii parasites, determined in tissue culture after a 24 h treatment period [10] . Apparent differences in IC 50 values should not be overinterpreted since these are strongly dependent on the fractional volume of the lipid phase. Assuming that a highly hydrophobic substance like HDQ will partition to the hydrophobic phase, the effective HDQ concentration for interaction with type-II NADH dehydrogenase may well differ by two orders of magnitude between the two assay systems. However, we can not exclude at present that HDQ inhibits other ubiquinone dependent NADH oxidoreductases such as succinate dehydrogenase, dihydroorotate dehydrogenase, glycerol-3-phosphate dehydrogenase and the malate: quinone oxidoreductase, in addition to type-II NADH dehydrogenases.
A long alkyl side chain of C 12 or C 14 at position 2 is critical for the inhibition of NADH:DBQ oxidoreductase activity. Compounds with short alkyl side chains of C 5 (HPQ) and C 6 (HHQ) with 3700 nM and 2300 nM displayed significantly higher IC 50 values as compounds with long alkyl side chains of C 12 (HDQ, IC 50 = 300 nM) and C 14 (HTQ, IC 50 = 300 nM). On the basis of structural similarities, it is tempting to speculate that 1-hydroxy-2-alkyl-4(1H)quinolones are likely to compete with ubiquinone for the same binding site. A long alkyl site chain leads to a higher hydrophobicity and is likely to render the physicochemical properties and the structure of 1-hydroxy-2-alkyl-4 (1H)quinolones more similar to ubiquinone. Another aspect is the partition of the compounds between aqueous and membrane lipid phase. Highly hydrophobic 1-hydroxy-2-alkyl-4(1H)quinolones as HDQ and HTQ, in contrast to those with smaller alkyl side chains, can be expected to partition almost quantitatively into the membrane lipid phase. The correlation between IC 50 values and length of the alkyl side chain mirrored the in vivo-efficiency of these drugs to inhibit parasite replication: HPQ (C 5 ) did not show any inhibitory effect at 10 nM, while parasite growth was reduced to more than 50% by HDQ and HTQ at this concentration [10] . A reevaluation of the efficiency of HHQ (C 6 ) to inhibit T. gondii replication yielded an IC 50 of 220 nM for HHQ (C 6 ), which is more than 50-fold higher than the IC 50 for HDQ (data not shown). Together, these data reveal that only 1-hydroxy-2-alkyl-4(1H)quinolones with long alkyl site chains are effective TgNDH2-I inhibitors and antiparasitic drugs.
